CliffBio
small molecule

TIGLUTIK KIT

RILUZOLE

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyITALFARMACO SA

Drug detail

Brand nameTIGLUTIK KIT
Active ingredientRILUZOLE
Strength50MG/10ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusRX

Listed patents

PatentExpiresType
8765150March 2029product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TIGLUTIK KIT patent cliff — loss of exclusivity March 2029 | CliffBio